| Objective:To observe the efficacy and safety of the combination and microtransplantation in the treatment of elder patiens with AML(acute myeloid leukemia).The results were expected to provide some reference for treatment of elderly patients with AML and improve the overall prognosis.Methods:70 elderly patients with AML were selected in our hospital from February 2012 to June 2016.Medical record information query,clinical physical status examination,laboratory examination and follow-up to were used to complete data collection.70 cases were divided into the following two groups by different treatment therapy:decitabine combined with chemotherapy(39 cases)and decitabine combined with microtransplantation(31 cases).The treatment effect,the overall survival and adverse reactions of the two groups were observed.Results:Among the 70 patients,45 were male ang 25 were female:the median age was 67 years old(60-74 years old),the median follow-up time was 29 moths(0.7-69.1months).The cumulative recurrence rate(CIR)of 2 years of comnination of microtransplantation with desecitabine and chemotherapy alone was 35.5%and 61.5%,respectively(K=4.382,p=0.036).the 2-year progression-free survival rate(PFS)of the the microtransplantation group(40.2%)was significantly higher than that of the chemotherapy group(11.7%)(K=8.582,p=0.004).The incidence of adverse reactions(45.1%)in the microtransplantation group was lower than that in the chemotherapy group(79.49%),and the differens was statistically significant(P=0.003).The 2-year overall survival(OS)rate in two groups was 80.6%and 12.8%,respectively(K=4.086,p=0.043)Conclusion:Clinical treatment effects of decitabine combined with microtransplantation therapy was better than that of the decitabine combined with chemotherapy group,The combined microtransplantation of dicitabine significantly reduced CIR,improved PFS and OS,and effectively reduced the incidencr of adverse reactions in elderly AML patients.Further more,GVHD clinically relevant performance was not observed. |